Company news
Biolinerx Ltd. (TASE:BLRX) news
Every Biolinerx Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 27, 2026
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
May 20, 2026
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
April 28, 2026
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
April 8, 2026
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
March 26, 2026
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
March 23, 2026
BioLineRx to Report 2025 Annual Results on March 23, 2026
March 16, 2026
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 24, 2025
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
November 18, 2025
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
November 17, 2025
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage ...
September 29, 2025
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
August 7, 2025
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Pre...
May 30, 2025
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 27, 2025
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
May 20, 2025
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
March 31, 2025
BioLineRx to Report 2024 Annual Results on March 31, 2025
March 24, 2025